Last reviewed · How we verify

Seganest — Portfolio Competitive Intelligence Brief

Seganest pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Extubation T Extubation T marketed
Extubation U Extubation U marketed Neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Fondation Ophtalmologique Adolphe de Rothschild · 1 shared drug class
  4. Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 shared drug class
  5. Galderma R&D · 1 shared drug class
  6. University of California, Los Angeles · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Seganest:

Cite this brief

Drug Landscape (2026). Seganest — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seganest. Accessed 2026-05-14.

Related